May 1, 2021Open Access

Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The European & Developing Countries Clinical Trials Partnership, Wellcome Trust, and National Institute for Health Research Oxford Biomedical Research Centre.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Datoo et al. (Sat,) studied this question.

synapsesocial.com/papers/69d91dbb9402b8412aa3c3b4 https://doi.org/https://doi.org/10.1016/s0140-6736(21)00943-0

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial2019 · 70 citations
2The effect of air pollution on human physiological function in China: a longitudinal study2015 · 424 citations
3Influenza Hemagglutinin Nanoparticle Vaccine Elicits Broadly Neutralizing Antibodies against Structurally Distinct Domains of H3N2 HA2020 · 45 citations
4Changes in Malaria Epidemiology in Africa and New Challenges for Elimination2016 · 307 citations
5Malaria incidence and prevalence during the first year of life in Nanoro, Burkina Faso: a birth-cohort study2018 · 47 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo